STOCK TITAN

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Edgewise Therapeutics (NASDAQ: EWTX), a muscle disease biopharmaceutical company, has announced its upcoming participation in the RBC Capital Markets Global Healthcare Conference. The presentation is scheduled for Tuesday, May 20, 2025, at 9:00 am ET. The event will feature a live webcast accessible through the company's Events & Presentations page, with replay availability for a limited time after the conference. Attendees are advised to connect several minutes before the start time to ensure proper connection.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction – EWTX

-2.28%
1 alert
-2.28% News Effect

On the day this news was published, EWTX declined 2.28%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 9:00 am ET.

The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedInX , Facebook and Instagram.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference-on-may-20-2025-302452775.html

SOURCE Edgewise Therapeutics

FAQ

When is Edgewise Therapeutics (EWTX) presenting at the RBC Capital Markets Healthcare Conference?

Edgewise Therapeutics will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 9:00 am ET.

How can investors access Edgewise Therapeutics' (EWTX) RBC Conference presentation?

The presentation will be available via live webcast on Edgewise's Events & Presentations page, with replay access available for a limited time after the conference.

What type of company is Edgewise Therapeutics (EWTX)?

Edgewise Therapeutics is a muscle disease biopharmaceutical company listed on the Nasdaq.

Where can I find the webcast link for EWTX's RBC Conference presentation?

The webcast link can be found on the Edgewise Events & Presentations page of the company's website.
Edgewise Therapeutics, Inc.

NASDAQ:EWTX

EWTX Rankings

EWTX Latest News

EWTX Latest SEC Filings

EWTX Stock Data

3.12B
85.98M
Biotechnology
Pharmaceutical Preparations
Link
United States
BOULDER